Table 2 Clinical characteristics of eptinezumab adverse event reports from the FAERS database (Q2 2020 – Q3 2024).
From: Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment
Characteristics | Case numbers | Case proportion (%) |
|---|---|---|
Number of events | 5306 | |
Gender | ||
Male | 558 | 10.5 |
Female | 3322 | 62.6 |
Missing | 1426 | 26.9 |
Age | ||
< 18 | 13 | 0.2 |
18–65 | 3175 | 59.8 |
65–85 | 528 | 10.0 |
> 85 | 9 | 0.2 |
Missing | 1581 | 29.8 |
Top 5 Reported Countries | ||
United States | 4974 | 93.7 |
Canada | 219 | 4.1 |
France | 26 | 0.5 |
The United Arab Emirates | 22 | 0.4 |
Germany | 9 | 0.2 |
Reporter | ||
Healthcare professional | 1063 | 20.0 |
Non-healthcare professional | 4215 | 79.5 |
Missing | 28 | 0.5 |
Reporting year | ||
2020 | 124 | 2.3 |
2021 | 735 | 13.9 |
2022 | 1191 | 22.4 |
2023 | 1596 | 30.1 |
2024(As of the third quarter) | 1660 | 31.3 |
